This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis | MicrobiomeTrials
← Back to trials NCT07720375
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-07-31Est. Completion: 2029-02-28
Enrollment target: 300 participantsOther microbiome trials you might be interested in Bronchiectasis Adult
Study design: observational, retrospective Population: 270 patients diagnosed with bronchiectasis (BX) treated at the Re…
A Coruña, Spain Est. completion Oct 1, 2026
Non-cystic Fibrosis Bronchiectasis
This is a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score at 24 weeks of…
Phoenix, United States Completed Oct 29, 2027
Phase 1
Recruiting
Healthy Participants Non-cystic Fibrosis Bronchiectasis
This is a Phase 1a/1b study to test the safety, tolerability, microbiological response, and pharmacokinetics of inhaled …
Miami, United States Est. completion Jun 2027